1971 related articles for article (PubMed ID: 30639376)
1. The interplay among gut microbiota, hypertension and kidney diseases: The role of short-chain fatty acids.
Felizardo RJF; Watanabe IKM; Dardi P; Rossoni LV; Câmara NOS
Pharmacol Res; 2019 Mar; 141():366-377. PubMed ID: 30639376
[TBL] [Abstract][Full Text] [Related]
2. Gut microbiota in chronic kidney disease.
Cigarran Guldris S; González Parra E; Cases Amenós A
Nefrologia; 2017; 37(1):9-19. PubMed ID: 27553986
[TBL] [Abstract][Full Text] [Related]
3. Contributory Role of Gut Microbiota and Their Metabolites Toward Cardiovascular Complications in Chronic Kidney Disease.
Li DY; Tang WHW
Semin Nephrol; 2018 Mar; 38(2):193-205. PubMed ID: 29602401
[TBL] [Abstract][Full Text] [Related]
4. The Impact of CKD on Uremic Toxins and Gut Microbiota.
Rysz J; Franczyk B; Ławiński J; Olszewski R; Ciałkowska-Rysz A; Gluba-Brzózka A
Toxins (Basel); 2021 Mar; 13(4):. PubMed ID: 33807343
[TBL] [Abstract][Full Text] [Related]
5. Prenatal androgen exposure causes hypertension and gut microbiota dysbiosis.
Sherman SB; Sarsour N; Salehi M; Schroering A; Mell B; Joe B; Hill JW
Gut Microbes; 2018; 9(5):400-421. PubMed ID: 29469650
[TBL] [Abstract][Full Text] [Related]
6. The gut microbiota and the brain-gut-kidney axis in hypertension and chronic kidney disease.
Yang T; Richards EM; Pepine CJ; Raizada MK
Nat Rev Nephrol; 2018 Jul; 14(7):442-456. PubMed ID: 29760448
[TBL] [Abstract][Full Text] [Related]
7. The crosstalk of gut microbiota and chronic kidney disease: role of inflammation, proteinuria, hypertension, and diabetes mellitus.
Kanbay M; Onal EM; Afsar B; Dagel T; Yerlikaya A; Covic A; Vaziri ND
Int Urol Nephrol; 2018 Aug; 50(8):1453-1466. PubMed ID: 29728993
[TBL] [Abstract][Full Text] [Related]
8. Rhubarb Enema Increasing Short-Chain Fatty Acids that Improves the Intestinal Barrier Disruption in CKD May Be Related to the Regulation of Gut Dysbiosis.
Ji C; Lu F; Wu Y; Lu Z; Mo Y; Han L; Lin Q; Liu X; Zou C
Biomed Res Int; 2022; 2022():1896781. PubMed ID: 35097110
[TBL] [Abstract][Full Text] [Related]
9. [Pathomechanism and treatment of gut microbiota dysbiosis in chronic kidney disease and interventional effects of Chinese herbal medicine].
Han WB; Liu YL; Wan YG; Sun W; Tu Y; Yang JJ; Wu W; He WM; Yao J
Zhongguo Zhong Yao Za Zhi; 2017 Jul; 42(13):2425-2432. PubMed ID: 28840678
[TBL] [Abstract][Full Text] [Related]
10. Unraveling mechanistic insights into the role of microbiome in neurogenic hypertension: A comprehensive review.
Dai Y; Shen Z; Khachatryan LG; Vadiyan DE; Karampoor S; Mirzaei R
Pathol Res Pract; 2023 Sep; 249():154740. PubMed ID: 37567034
[TBL] [Abstract][Full Text] [Related]
11. Chronic Kidney Disease and Gut Microbiota: What Is Their Connection in Early Life?
Hsu CN; Tain YL
Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409313
[TBL] [Abstract][Full Text] [Related]
12. Current understanding of microbiota- and dietary-therapies for treating inflammatory bowel disease.
Eom T; Kim YS; Choi CH; Sadowsky MJ; Unno T
J Microbiol; 2018 Mar; 56(3):189-198. PubMed ID: 29492876
[TBL] [Abstract][Full Text] [Related]
13. The gut microbiota as a novel regulator of cardiovascular function and disease.
Battson ML; Lee DM; Weir TL; Gentile CL
J Nutr Biochem; 2018 Jun; 56():1-15. PubMed ID: 29427903
[TBL] [Abstract][Full Text] [Related]
14. Gut microbiota-derived short-chain fatty acids and hypertension: Mechanism and treatment.
Yang F; Chen H; Gao Y; An N; Li X; Pan X; Yang X; Tian L; Sun J; Xiong X; Xing Y
Biomed Pharmacother; 2020 Oct; 130():110503. PubMed ID: 34321175
[TBL] [Abstract][Full Text] [Related]
15. Gut microbiota in kidney disease and hypertension.
Antza C; Stabouli S; Kotsis V
Pharmacol Res; 2018 Apr; 130():198-203. PubMed ID: 29496593
[TBL] [Abstract][Full Text] [Related]
16. Gut Microbiota-Kidney Cross-Talk in Acute Kidney Injury.
Gong J; Noel S; Pluznick JL; Hamad ARA; Rabb H
Semin Nephrol; 2019 Jan; 39(1):107-116. PubMed ID: 30606403
[TBL] [Abstract][Full Text] [Related]
17. Quantitative reduction in short-chain fatty acids, especially butyrate, contributes to the progression of chronic kidney disease.
Wang S; Lv D; Jiang S; Jiang J; Liang M; Hou F; Chen Y
Clin Sci (Lond); 2019 Sep; 133(17):1857-1870. PubMed ID: 31467135
[TBL] [Abstract][Full Text] [Related]
18. Maternal Adenine-Induced Chronic Kidney Disease Programs Hypertension in Adult Male Rat Offspring: Implications of Nitric Oxide and Gut Microbiome Derived Metabolites.
Hsu CN; Yang HW; Hou CY; Chang-Chien GP; Lin S; Tain YL
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 33008046
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the impact of gut microbiota on uremic solute accumulation by a CE-TOFMS-based metabolomics approach.
Mishima E; Fukuda S; Mukawa C; Yuri A; Kanemitsu Y; Matsumoto Y; Akiyama Y; Fukuda NN; Tsukamoto H; Asaji K; Shima H; Kikuchi K; Suzuki C; Suzuki T; Tomioka Y; Soga T; Ito S; Abe T
Kidney Int; 2017 Sep; 92(3):634-645. PubMed ID: 28396122
[TBL] [Abstract][Full Text] [Related]
20. Prebiotic administration modulates gut microbiota and faecal short-chain fatty acid concentrations but does not prevent chronic intermittent hypoxia-induced apnoea and hypertension in adult rats.
O'Connor KM; Lucking EF; Bastiaanssen TFS; Peterson VL; Crispie F; Cotter PD; Clarke G; Cryan JF; O'Halloran KD
EBioMedicine; 2020 Sep; 59():102968. PubMed ID: 32861200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
